arrow
A

Aurélien Marabelle

INSERM
H指数:87
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial

双特异性双T细胞激动剂invikafusp alfa在实体瘤中的研究:第1/2期START-001试验

2026-10-230
PRE
Development and external validation of a prognostic score associated with poor outcomes in patients receiving immune checkpoint blockade-containing therapies enrolled in early-phase clinical trials

基于早期临床试验中接受免疫检查点阻断治疗患者的预后评分的开发与外部验证:与不良结局相关的评分

2026-07-010
PRE
Future approaches to immune base biomarkers

免疫基础生物标志物的未来方法

2026-06-060
PRE
Acute kidney injury in patients included in early-phase oncology clinical trials, results of the AKITEP study

早期肿瘤学临床试验纳入患者中的急性肾损伤,AKITEP研究的结果

2026-05-260
PRE
Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study

帕博利珠单抗单药治疗微卫星高度不稳定或错配修复缺陷型复发性胶质瘤:来自多队列KEYNOTE-158研究的结果

2026-04-010
PRE
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours

W0180作为抗-VISTA单克隆抗体,在局部晚期或转移性实体瘤患者中的首次人体1期剂量递增研究,包括单独使用和联合帕博利珠单抗

2026-02-011
OA
Single-cell Transcriptome Profiling of Post-treatment and Treatment-naïve Colorectal Cancer: Insights into Putative Mechanisms of Chemoresistance

治疗后与初治结直肠癌的单细胞转录组分析:化疗耐药潜在机制的见解

2025-11-090
PRE
Collagenous colitis in patients treated for cancer: role of immune checkpoint inhibitors. Clinical, histological and immunological features in 15 cases

胶原性结肠炎在癌症治疗患者中的发生:免疫检查点抑制剂的潜在作用。15例患者的临床、组织学和免疫学特征

2025-08-060
OAAI
Age Does not Affect the Efficacy of Antibody Drug Conjugates, But is Associated with High-Grade Adverse Events in Patients with Cancer Enrolled in Early Phase Clinical Trials

年龄不影响抗体药物偶联物的疗效,但与在早期临床试验中入组的癌症患者发生高等级不良事件相关。

2025-05-160
PRE
Infectious Complications in Patients Treated With T-cell Engagers as Cancer Immunotherapies, a Descriptive Study From the REISAMIC Registry

T细胞接合剂作为癌症免疫疗法治疗患者的感染并发症:一项来自REISAMIC登记研究的描述性研究

2025-04-010
PRE
Pembrolizumab in microsatellite-instability-high and mismatch-repair-deficient advanced solid tumors: updated results of the KEYNOTE-158 trial

帕博利珠单抗在微卫星高度不稳定和错配修复缺陷型晚期实体瘤中的研究:KEYNOTE-158试验的更新结果

2025-02-200
PRE
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results

帕博利珠单抗在微卫星高度不稳定/错配修复缺陷(MSI-H/dMMR)和非微卫星高度不稳定/非错配修复缺陷(non-MSI-H/non-dMMR)晚期子宫内膜癌中的疗效:KEYNOTE-158研究II期结果

2025-02-012
PRE
Efficacy of anti-PD1 therapy in extranodal NK/T cell lymphoma: A matched cohort analysis from the LYSA

抗PD1疗法在结外NK/T细胞淋巴瘤中的疗效:一项来自LYSA的匹配队列分析

2025-01-200
OA
Antecedent viral immunization and efficacy of immune checkpoint blockade: an extensive serum antibody profile to predict outcomes in non-small cell lung cancer
2024-11-280
OAAI
The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development

ESMO肿瘤不可知分类器和筛选器 (etac-s): 一种评估分子引导疗法的肿瘤不可知潜力和指导药物开发的工具

2024-11-012
OAAI